



Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies

Xiaofei Li*, Shuang Wu and Yuexiao Yu

Department of Infectious Diseases, Yiwu Central Hospital, Yiwu, China

Background: The association between aspirin use and the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV) or hepatitis C (HCV) virus infection remains not fully determined. A meta-analysis was performed to summarize the findings of cohort studies.

Methods: Relevant cohort studies were retrieved via a search of PubMed Cochrane's Library and Embase databases. A random-effect model was used to pool the results. Subgroup analyses were performed to evaluate the influence of study characteristics on the association.

OPEN ACCESS

Edited by:

Zhiliang Hu, Nanjing Second Hospital, China

Reviewed by:

Peng Huang, Nanjing Medical University, China Rui Huang, Nanjing Drum Tower Hospital, China

*Correspondence: Xiaofei Li metshep@sina.com

Specialty section:

This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine

Received: 05 June 2020 Accepted: 23 November 2020 Published: 08 January 2021

Citation:

Li X, Wu S and Yu Y (2021) Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front. Med. 7:569759. doi: 10.3389/fmed.2020.569759 **Results:** Seven cohort studies with 120,945 adult patients with HBV or HCV infection were included. Pooled results showed that aspirin use was independently associated with a reduced risk of HCC in these patients (risk ratio: 0.73, 95% confidence interval: 0.64 to 0.83, p < 0.001; $l^2 = 86\%$). Subgroup analyses showed that aspirin use was associated with a reduced HCC risk regardless of the viral type, age, sex, the diabetic, and cirrhotic status of the patients, and the follow-up durations. Moreover, consistent results were obtained in studies with and without adjustment of antiviral treatment and statin use. Pooled results of four studies showed that aspirin use was associated with an increased risk of gastrointestinal bleeding in these patients (risk ratio: 1.15, 95% confidence interval: 1.02 to 1.28, p = 0.02; $l^2 = 0\%$).

Conclusions: Aspirin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection, whereas the risk of gastrointestinal bleeding may be increased. These results should be validated in clinical trials.

Keywords: aspirin, hepatocellular carcinoma, hepatitis B virus, hepatitis C virus, cirrhosis, gastrointestinal bleeding, meta-analysis

INTRODUCTION

Hepatocellular carcinoma (HCC) is a common malignancy of the digestive system (1). Epidemiology studies showed that each year, \sim 500,000 patients were diagnosed with HCC worldwide (1). Moreover, treatment strategies for HCC remain limited in current clinical practice, which attributes to the relatively high mortality in these patients (2, 3). Hepatitis B virus (HBV)

1

or hepatitis C virus (HCV) infection is the known risk factor for the development of HCC (4–6). Although extensive use of medications for HBV suppression or HCV eradication could reduce the incidence of HCC in these patients, patients with HBV or HCV infection remain at high risk for the development of HCC (7, 8). Accordingly, prophylactic measures for HCC in these high-risk patients remain of great clinical significance (9).

Aspirin (acetylsalicylic acid) is a commonly used nonsteroidal anti-inflammatory drugs (10). Via irreversible inactivation of cyclooxygenase, aspirin exerts multiple pharmacological effects, including antiplatelet and anti-inflammation (11). Aspirin is a cornerstone for the prevention and treatment of atherosclerotic cardiovascular diseases (12). Moreover, increasing evidence suggests that aspirin may have anticancer efficacy (13). The use of aspirin has been related to reduced incidences of endometrial cancer (14), gastric cancer (15), digestive tract cancers (16), pancreatic cancer, among others (17), whereas studies that evaluated the association between aspirin use and risk of HCC in patients with HBV or HCV infection showed inconsistent results (18-24). Although a recent meta-analysis showed that aspirin might be associated with a reduced risk of HCC in a mixed population, meta-analyses limited to patients with HBV or HCV infection have not been performed (25). Besides, some largescale cohort studies (22-24) focusing on the association between aspirin use and HCC risk in patients with HBV or HCV infection have been published but never been evaluated in a meta-analysis. Moreover, whether aspirin use is associated with an increased risk of gastrointestinal bleeding (GIB) in patients with HBV or HCV infection remains unknown. Therefore, in this study, we aimed to perform a meta-analysis of cohort studies to systematically evaluate the influence of aspirin use on the risks of HCC and GIB in patients with HBV or HCV infection.

METHODS

The meta-analysis was performed in accordance with the Metaanalysis of Observational Studies in Epidemiology (26) and Cochrane's Handbook (27) guidelines.

Literature Search

Studies were identified via a systematic search of electronic databases of PubMed, Cochrane's Library, and Embase via the following combined terms: ("aspirin" OR "antiplatelet") AND ("chronic hepatitis B" OR "chronic hepatitis C" OR "hepatitis B virus" OR "hepatitis C virus" OR "HBV" OR "HCV"). The combined terms were entered into the databases as a single search. We used this keywords search strategy instead of those searched as "text words" or as "Mesh terms" to retrieve more comprehensive records. The search was limited to human studies without language restriction. The reference lists of related original and review articles were also analyzed using a manual approach. The final literature search was performed on November 19, 2020.

Study Selection

The inclusion criteria for the studies were (1) cohort studies published as full-length articles; (2) included at least 1,000

Aspirin and HCC Risk

adult patients with HBV or HCV infection but without HCC at baseline; (3) evaluated the association between aspirin use and the incidences of HCC (primary outcome) and/or GIB (secondary outcome) during a follow-up duration >1 year; and (4) reported the relative risk for the association with multivariate analyses and adjustment of confounding factors. Reviews, editorials, preclinical studies, and studies irrelevant to the aim of the current meta-analysis were excluded. Conference proceedings and unpublished data were not considered for this meta-analysis because these reports may not be strictly peerreviewed, and including of these reports may confound the results of the meta-analysis.

Data Extracting and Quality Evaluation

Literature search, data extraction, and quality assessment of the included studies were performed according to the predefined inclusion criteria independently by two authors. Discrepancies were resolved by consensus or discussion with the corresponding author. The extracted data included (1) name of the first author, publication year, and country where the study was performed; (2) study design characteristics; (3) patient characteristics, including disease status, sample size, age, sex, prevalence of diabetes, and proportions of patients with cirrhosis at baseline; (4) dose and definition of aspirin use; (5) follow-up durations; (6) strategy for HCC validation and number of HCC cases during follow-up; and (7) confounding factors that were adjusted in the multivariate analyses. The quality of each study was evaluated using the Newcastle-Ottawa Scale (28), which ranges from 1 to 9 stars and judges each study regarding three aspects: selection of the study groups; the comparability of the groups; and the ascertainment of the outcome of interest.

Statistical Analyses

Risk ratios (RRs) and their corresponding 95% confidence intervals (CIs) were selected as the general measure for the association between aspirin use and HCC risk in patients with HBV or HCV infection. For studies that reported adjusted RR data in various multivariate-analysis models, the one with the most adequately adjusted variables were used for the metaanalysis. Data of RRs and their corresponding stand errors were calculated from 95% CIs or p values and logarithmically transformed to stabilize variance and normalized the distribution (27). The Cochrane's Q test was used to evaluate the heterogeneity among the included cohort studies and the estimation of the I^2 statistic (29). Significant heterogeneity was considered if I^2 > 50%. We used a random-effect model to synthesize the RR data because this model could incorporate the heterogeneity among the included studies and retrieve a more generalized outcome (27). For the primary outcome of HCC incidence, sensitivity analyses, by omitting one individual study at a time, were performed to test the robustness of the results (30). Predefined subgroup analyses were performed to evaluate the influences of study characteristics on the outcome, such as the viral type, age, sex, diabetic status, and cirrhotic status of the patients, the exposure time of aspirin, follow-up durations, and the adjustment of antiviral treatment and statin use. Medians of the continuous variables were used as cutoff values for defining




FIGURE 1 | Flowchart of database search and study identification.

the subgroups. The potential publication bias was assessed by visual inspection for the symmetry of the funnel plots. Moreover, Egger's regression asymmetry test (31) was also performed if at least 10 datasets were included in the meta-analysis. If a significant publication was suggested, a trim-and-fill analysis was performed. This method incorporated hypothesized unpublished studies with negative results to generate symmetrical forest plots (27). A *p*-value < 0.05 was considered statistically significant. We used RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) and STATA software for the meta-analysis and statistics.

RESULTS

Literature Search

The process of database search is summarized in **Figure 1**. Briefly, 701 articles were found via initial literature search of the PubMed, Cochrane's Library, and Embase databases, and 677 were excluded through screening of the titles and abstracts mainly because they were not relevant to the purpose of the metaanalysis. Subsequently, 24 potential relevant records underwent full-text review. Of these, 17 were further excluded based on the reasons listed in **Figure 1**. Finally, seven articles were included (18–24).

Study Characteristics and Quality Evaluation

The characteristics of the included studies are summarized in **Table 1**. All of the included studies were retrospective cohort studies except for one study, which was a prospective cohort study (24). These studies were published between 2017 and 2020 and included adult patients with HBV or HCV from South Korea (18, 20), China (19, 21–23), and Sweden (24). Because one study reported the association between aspirin use and HCC risk in patients with HBV and HCV infection separately (19), these datasets were included independently. Overall, eight

TABLE 1 | Characteristics of the included cohort studies.

Study	Country	Design	Patient characteristics	Sample size	Mean age	Male	Aspirin user	Cirrhosis	Aspirin dose and validation	Follow-up timespan and mean durations	HCC validation	HCC cases	Variables adjusted	NOS
					years	%		%		years				
_ee et al. [18)	South Korea	RC	Patients with HBV infection on antiviral treatment	1,674	51.9	63.0	343	12.2	Aspirin 100 mg/day for primary and secondary prevention of CVD validated by medical records	2002–2015, mean: 4.8	Serum AFP, ultrasonography, contrast- enhanced liver CT or MRI	63	Age, sex, DM, cirrhosis, Child-Pugh score, MELD score, HBeAg, ALT, albumin, total bilirubin, SCr, PT, and platelet count	8
Ho et al. (19)-HBV	China	RC	HBV patients with hypertension	7,724	57.4	66.2	3,575	78.9	Aspirin used for antiplatelet therapy	2005–2014, mean: 4	Histological confirmation or typical imaging presentation	552	Age, sex, low economic income, other comorbidities, and concurrent use of ACEI/ARB, metformin, and statin	7
Ho et al. (19)-HCV	China	RC	HCV patients with hypertension	7,873	59.5	49.3	3,349	88	Aspirin used for antiplatelet therapy	2005–2014, mean: 4.6	Histological confirmation or typical imaging presentation	503	Age, sex, low economic income, other comorbidities, and concurrent use of ACEI/ARB, metformin, and statin	7
Hwang et al. (20)	South Korea	RC	Patients with HBV or HCV infection	31,528	50.0	53.6	NR	NR	Regular aspirin prescription records (>30 days) within a 5-year before the index date	2007–2013, mean: 6.4	ICD-10	773	Age, sex, BMI, health behaviors, concurrent medication, BP, FPG,TC, socioeconomic status, and CCI	7
Lee et al. (21)	China	RC	Patients with chronic HBV infection	10,615	58.8	72.4	2,123	17.1	Regular aspirin prescription records (>90 days); Mostly (98%) of aspirin (100 mg/day) for CVD prevention	1997–2012, mean: 5	ICD-9	697	Age, sex, liver cirrhosis, DM, hyperlipidemia, hypertension, statin use, metformin use, and antiviral therapy	7
Liao et al. (23)	China	RC	Patients with newly diagnosed HCV infection	3,822	64.5	47.1	1,911	NR	Aspirin 100 mg/day for antiplatelet therapy	2000–2012, mean: 4	ICD-9	147	Age, sex, hypertension, DM, moderate or severe liver disease, MI, CHF, ischemic stroke, anti-hypertension agents, hypoglycemic agents, and heparin, other antithrombotic agents and NSAIDs	6
Lee et al. (22)	China	RC	Patients with chronic HCV infection	7,434	63.2	44.3	2,478	15.7	Regular aspirin use of 100 mg/day prescribed for >90 days	1997–2011, mean: 5	ICD-9	436	Age, sex, cirrhosis, liver decompensation, hyperlipidemia, statin use, and interferon therapy	7
Simon et al. (24)	Sweden	PC	Patients with chronic HBV or HCV infection	50,275	42.7	66.2	14,205	14.0	Regular aspirin use of 75 or 160 mg/day prescribed for >90 days		ICD-9	1612	Age, sex, liver disease severity, antiviral treatment, DM, hypertension, obesity, or alcohol abuse or misuse, and use of insulin, metformin, and statins	9

Aspirin and HCC Risk

HCC, hepatocellular carcinoma; NOS, Newcastle–Ottawa Scale; RC, retrospective cohort; PC, prospective cohort; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reported; CVD, cardiovascular diseases; AFP, alpha fetoprotein; CT, computed tomography; MRI, magnetic resonance imaging; DM, diabetes mellitus; MELD, model for end-stage liver disease; ALT, alanine transaminase; SCr, serum creatinine; PT, prothrombin time; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; FPG, fasting plasma glucose; TC, total cholesterol; CI, Charlson comorbidity index; MI, myocardial infarction; CHF, congestive heart failure; NSAIDs, nonsteroidal anti-inflammatory drugs; ICD, International Classification of Diseases.

References	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Outcome not present at baseline	Control for age and sex	Control for age Control for other Assessment of and sex confounding outcome factors	Assessment of outcome	Enough long follow-up duration	Adequacy of follow-up of cohorts	Total
Lee et al. (18)	-	-	-	-	-	0	-	-	-	œ
Ho et al. (19)-HBV	0	-	-	÷	-	0	÷	-	-	7
Ho et al. (19)-HCV	0	-	-	۳	-	0	£	-	-	2
Hwang et al. (20)	-	-	0	-	-	-	0	-	-	7
Lee et al. (21)	F	-	÷	1	1	0	0	-	1	7
Liao et al. (23)	-		0	÷	+-	0	0	, -	.	9
Lee et al. (22)	F		Ţ.	Ļ	+	0	0	-	+	7
Simonet et al. (24)	-	-	-	-	-	-	-	-	-	ŋ

datasets from seven cohort studies, with 120,945 adult patients with HBV or HCV infection, were included (18-24). The mean age of the included patients varied from 42 to 65 years, with proportions of males ranging from 44 to 73%. Aspirin use was generally validated by medicine prescription records, which were prescribed at a dose of 100 mg/day in four studies (18, 21-23), of 75 or 160 mg/day in one study (24), whereas the other two studies did not specify the dose of aspirin (19, 20). The follow-up duration varied from 4.0 to 7.9 years. Diagnosis of HCC was based on clinical data in two studies (18, 19) and the International Classification of Diseases version 9 or 10 codes in the other five (20-24). A total of 4,783 HCC cases occurred during follow-up. Potential confounding factors, such as age, sex, diabetic status, alcohol intake, comorbidities, and concurrent medications, were adjusted when presenting the outcome in all of the included studies. The Newcastle-Ottawa Scale scores of the included studies ranged from six to nine, indicating generally good study quality (Table 2).

Primary Outcome

Pooled results of eight datasets (18–24) with a random-effect model showed that aspirin use was associated with a reduced risk of HCC in patients with HBV or HCV infection (RR: 0.73, 95% CI: 0.64 to 0.83, p < 0.001; **Figure 2A**) with significant heterogeneity (p for Cochrane's Q test = 0.002, I² = 70%). Results of sensitivity analyses by omitting one dataset at a time did not significantly change the results (RR: 0.70 to 0.75, p all < 0.05). Specifically, excluding the only prospective cohort study showed similar results (RR: 0.73, 95% CI: 0.62 to 0.87, p < 0.001; I² = 72%).

Subgroup analyses showed that aspirin use was associated with a reduced HCC incidence in patients with HBV (RR: 0.70, 95% CI: 0.58 to 0.85, p < 0.001; $I^2 = 52\%$) and HCV infection (RR: 0.76, 95% CI: 0.61 to 0.94, p = 0.01; $I^2 =$ 80%; p for subgroup difference = 0.59; Figure 2B). Definitions for the elderly were in accordance with the criteria of the original studies, which were defined as >60 years in two studies (21, 23) and >65 in the other two studies (22, 24). Results of subgroup analyses also showed that aspirin use was associated with a reduced HCC risk in patients with HBV or HCV infection regardless of the age, sex, diabetic status, and cirrhotic status of the patients (Figures 3A,B, 4A,B). Because different cutoff values for the aspirin exposure time were used in the original studies, we compared the association between aspirin use and HCC risk in the infected patients with the longest and the shortest categories of aspirin exposure time. Results showed that the association was stronger in patients with the longest categories of aspirin exposure time (RR: 0.54, 95% CI: 0.44 to 0.66, p < 0.001; $I^2 = 0\%$) compared with that in patients with the shortest categories (RR: 0.74, 95% CI: 0.60 to 0.91, p = 0.005; $I^2 = 56\%$; p for subgroup difference = 0.04; Figure 5A). Moreover, subgroup analyses according to the follow-up durations, adjustment of antiviral treatment, and adjustment of statin use consistently showed a significant association between aspirin use and reduced risk of HCC in these patients (Figures 5B, 6A,B). However, the association between aspirin use and reduced risk of HCC was

					Risk Ratio		Ris	k Rat	io		
Study	or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI		V, Rano	dom,	95% (
Lee 20	17	-1.34707365	0.53745932	1.5%	0.26 [0.09, 0.75]						
Ho 201	8-HBV	-0.19845094	0.10470099	13.6%	0.82 [0.67, 1.01]		-	•			
Ho 201	8-HCV	0.01980263	0.09935326	14.1%	1.02 [0.84, 1.24]			+			
Hwang	2018	-0.43078292	0.10820338	13.3%	0.65 [0.53, 0.80]		-	•			
Lee 20	19	-0.34249031	0.10048579	14.0%	0.71 [0.58, 0.86]		-	-			
Liao 20	20	-0.5798185	0.13149643	11.5%	0.56 [0.43, 0.72]		-				
Lee 20	20	-0.24846136	0.10076373	14.0%	0.78 [0.64, 0.95]		-	-			
Simon	2020	-0.37106368	0.05193851	18.0%	0.69 [0.62, 0.76]		•				
Total (95% CI)			100.0%	0.73 [0.64, 0.83]		•	•			
Hetero	geneity: Tau² =	0.02; Chi ² = 23.16	, df = 7 (P = 0	.002); I² =	70%	0.1 0.2	0.5	1	2	-+	
Test fo	r overall effect:	Z = 4.67 (P < 0.00	001)			0.1 0.2	0.5	1	2	Э	10
					Risk Ratio			k Rat			
	or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% Cl		V, Rano	<u>dom,</u>	95%		
1.2.1 H	BV										
Lee 20	17	-1.34707365	0.53745932	1.6%	0.26 [0.09, 0.75]						
Ho 201	8-HBV	-0.19845094	0.10470099	13.9%	0.82 [0.67, 1.01]		-	•			
Lee 20	19	-0.34249031	0.10048579	14.3%	0.71 [0.58, 0.86]			-			
Simon	2020	-0.4462871	0.11442569	13.1%	0.64 [0.51, 0.80]			-			
Subtot	al (95% Cl)			42.9%	0.70 [0.58, 0.85]		•				
Hetero	geneity: Tau ² =	0.02; Chi ² = 6.20,	df = 3 (P = 0.1	10); l² = 52	2%						
Test fo	r overall effect:	Z = 3.70 (P = 0.00	02)								
1.2.2 H	CV										
Ho 201	8-HCV	0.01980263	0.09935326	14.3%	1.02 [0.84, 1.24]			+			
Lee 20	20	-0.24846136	0.10076373	14.2%	0.78 [0.64, 0.95]		-	-			
Liao 20)20	-0.5798185	0.13149643	11.8%	0.56 [0.43, 0.72]						
Simon	2020	-0.34249031	0.07017941	16.7%	0.71 [0.62, 0.81]		-				
Subtot	al (95% Cl)			57.1%	0.76 [0.61, 0.94]						
	• •	0.04; Chi ² = 15.17 Z = 2.55 (P = 0.01		.002); l² =	80%						
			,	400.00/	0 70 10 04 0 041						
•	95% CI)			100.0%	0.73 [0.64, 0.84]			<u> </u>			
	• •	0.02; Chi ² = 22.06 Z = 4.47 (P < 0.00	•	.002); l ² =	68%	0.1 0.2	0.5	1	2	5	1
163110		erences: Chi ² = 0.2									

meta-analysis. (B) Subgroup analyses according to the viral type.

weakened in studies after adjustment of statin use (RR: 0.79, 95% CI: 0.68 to 0.91, p < 0.001; $I^2 = 70\%$) compared with that in studies without adjustment of statin use (RR: 0.58, 95% CI: 0.46 to 0.74, p < 0.001; $I^2 = 38\%$; p for subgroup difference = 0.03; **Figure 6B**).

Secondary Outcome

The meta-analysis by pooling the results of four studies (18, 21, 22, 24) showed that aspirin use was associated with an increased risk of GIB in patients with HBV or HCV infection (RR: 1.15, 95% CI: 1.02 to 1.28, p = 0.02; $I^2 = 0\%$; **Figure 7**). No subgroup analysis was performed because only four studies were included.

Publication Bias

The funnel plots regarding the association between aspirin use and HCC risk in patients with HBV or HCV infection are shown in **Figure 8A**. The funnel plots were asymmetrical on visual inspection, suggesting the potential risk of publication bias. Egger's regression test was not performed because only eight datasets were included. With a trim-and-fill analysis, one hypothesized study with negative results was imputed (**Figure 8A**) to achieve funnel plots. Including this study into the meta-analysis did not significantly change the results (RR: 0.74, 95% CI: 0.64 to 0.85, p < 0.001; $I^2 = 70\%$; **Figure 8B**). Publication bias regarding the association between aspirin use and GIB risk was unable to be analyzed due to the limited studies included.

				Risk Ratio	Risk	
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Rando	<u>m, 95% Cl</u>
1.3.1 Elderly						
Lee 2019		0.13591952	10.0%	0.71 [0.54, 0.93]		
Liao 2020		0.14716515	8.5%	0.55 [0.41, 0.73]		
Lee 2020	-0.37106368		11.8%	0.69 [0.54, 0.88]		
Simon 2020	-0.37106368	0.07234064	34.2%	0.69 [0.60, 0.80]		
Subtotal (95% CI)			64.5%	0.67 [0.61, 0.75]	•	
Heterogeneity: Tau ² : Test for overall effect		•	53); l² = 0%	6		
1.3.2 Non-elderly						
Lee 2019	-0.34249031	0 1/887372	8.3%	0.71 [0.53, 0.95]	_	
Liao 2020		0.30123734	2.0%	0.64 [0.35, 1.16]		_
Lee 2020	-0.09431068		2.0 <i>%</i> 7.0%	0.91 [0.66, 1.25]		
Simon 2020	-0.51082562		18.2%	0.60 [0.49, 0.73]	_ _	
Subtotal (95% CI)	-0.01002002	0.10001074	35.5%	0.70 [0.57, 0.85]		
Heterogeneity: Tau ²	= 0 02 [.] Chi ² = 4 89	df = 3 (P = 0.1)			•	
Test for overall effect			10), 1 – 00	70		
Total (95% CI)			100.0%	0.68 [0.62, 0.73]	•	
Heterogeneity: Tau ² :	= 0.00; Chi ² $= 7.09$	df = 7 (P = 0.4)	(2): $ ^2 = 19$			
	0.00, 0 1.00,	S (. S.				1.5 2
	Z = 9.11 (P < 0.00)	001)			0.5 0.7 1	1.5 2
Test for overall effect	,	,	0.75), l² =		0.5 0.7 1	1.J Z
	,	,	0.75). l² =		0.5 0.7 1	1.5 2
Test for overall effect	,	,	0.75). l² =		0.5 0.7 1 Risk I	
Test for overall effect Test for subaroup diff	ferences: Chi ² = 0.1	0. df = 1 (P =		0%		Ratio
Test for overall effect Test for subaroup diff	ferences: Chi ² = 0.1	0. df = 1 (P =		0% Risk Ratio	Risk I	Ratio
Test for overall effect Test for subaroup diff	ferences: Chi ² = 0.1	0. df = 1 (P = <u>SE</u>		0% Risk Ratio	Risk I	Ratio
Test for overall effect Test for subaroup diff <u>Study or Subgroup</u> 1.4.1 Women	ferences: Chi ² = 0.1	0. df = 1 (P = <u>SE</u> 0.27098078	Weight	0% Risk Ratio IV, Random, 95% Cl	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918	0. df = 1 (P = <u>SE</u> 0.27098078 0.19780237	Weight 5.0%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455	0. df = 1 (P = <u>SE</u> 0.27098078 0.19780237 0.13834803	Weight 5.0% 8.4% 13.9% 17.6%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% CI)	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261	Weight 5.0% 8.4% 13.9% 17.6% 44.8%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² =	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57,	0. df = 1 (P = <u>SE</u> 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3	Weight 5.0% 8.4% 13.9% 17.6% 44.8%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% CI)	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57,	0. df = 1 (P = <u>SE</u> 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3	Weight 5.0% 8.4% 13.9% 17.6% 44.8%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001)	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I ² = 16	0% Risk Ratio IV. Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] %	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, ; Z = 5.22 (P < 0.00 -0.28768207	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I ² = 16 18.5%	0% Risk Ratio IV. Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I² = 16 18.5% 10.2%	0% Risk Ratio IV, Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, ; Z = 5.22 (P < 0.00 -0.28768207 -0.52763274 -0.10536052	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I² = 16 18.5% 10.2% 14.1%	0% Risk Ratio IV. Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020 Simon 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I² = 16 18.5% 10.2% 14.1% 12.5%	0% Risk Ratio IV. Random. 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18] 0.59 [0.44, 0.79]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020 Simon 2020 Simon 2020 Subtotal (95% CI)	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274 -0.10536052 -0.52763274	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217 0.14994558	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 31); I² = 16 18.5% 10.2% 14.1% 12.5% 55.2%	0% Risk Ratio IV. Random. 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18] 0.59 [0.44, 0.79] 0.71 [0.59, 0.86]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020 Simon 2020	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274 -0.10536052 -0.52763274 = 0.02; Chi ² = 5.88,	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217 0.14994558 df = 3 (P = 0.1	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 31); I² = 16 18.5% 10.2% 14.1% 12.5% 55.2%	0% Risk Ratio IV. Random. 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18] 0.59 [0.44, 0.79] 0.71 [0.59, 0.86]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020 Simon 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² =	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274 -0.10536052 -0.52763274 = 0.02; Chi ² = 5.88,	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217 0.14994558 df = 3 (P = 0.1	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 31); I² = 16 18.5% 10.2% 14.1% 12.5% 55.2%	0% Risk Ratio IV. Random. 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18] 0.59 [0.44, 0.79] 0.71 [0.59, 0.86]	Risk I	Ratio
Test for overall effect Test for subaroup diff Study or Subgroup 1.4.1 Women Lee 2019 Liao 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect 1.4.2 Men Lee 2019 Liao 2020 Lee 2020 Simon 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect	ferences: Chi ² = 0.1 log[Risk Ratio] -0.73396918 -0.67334455 -0.41551544 -0.32850407 = 0.01; Chi ² = 3.57, : Z = 5.22 (P < 0.00 -0.28768207 -0.52763274 -0.10536052 -0.52763274 = 0.02; Chi ² = 5.88, : Z = 3.52 (P = 0.00	0. df = 1 (P = SE 0.27098078 0.19780237 0.13834803 0.11306261 df = 3 (P = 0.3 001) 0.10758307 0.17376811 0.13688217 0.14994558 df = 3 (P = 0.1 04)	Weight 5.0% 8.4% 13.9% 17.6% 44.8% 81); I² = 16 18.5% 10.2% 14.1% 12.5% 55.2% 12); I² = 49 100.0%	0% Risk Ratio IV. Random, 95% CI 0.48 [0.28, 0.82] 0.51 [0.35, 0.75] 0.66 [0.50, 0.87] 0.72 [0.58, 0.90] 0.64 [0.54, 0.75] % 0.75 [0.61, 0.93] 0.59 [0.42, 0.83] 0.90 [0.69, 1.18] 0.59 [0.44, 0.79] 0.71 [0.59, 0.86] % 0.67 [0.59, 0.76]	Risk I	Ratio <u>m, 95% CI</u>

FIGURE 3 | Subgroup analyses for the meta-analysis of the association between aspirin use and HCC incidence in patients with HBV or HCV infection. (A) Subgroup analyses according to the age of the patients. (B) Subgroup analyses according to the gender of the patients.

DISCUSSION

In this meta-analysis cohort study, we found that aspirin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection. Subgroup analyses showed that the significance of the association was not affected by the viral type, age, sex, diabetic status, the cirrhotic status of the patients, and follow-up durations, suggesting the robustness of the findings. Although consistent results were obtained in subgroup analyses according to the adjustment of antiviral treatment and statin use,

	04	la al Diala Datial	05	Malak	Risk Ratio			Ratio	~	
	Study or Subgroup	log[Risk Ratio]	<u> 3E</u>	weight	IV, Random, 95% CI	<u> </u>	Rando	<u>m, 95%</u>		
	1.5.1 DM	0 07057000	0.4.704000	7.00/	0.00.00.70.4.041		_	_		
	Ho 2018-HBV	-0.07257069		7.8%	0.93 [0.70, 1.24]					
	Ho 2018-HCV	-0.22314355		7.1%	0.80 [0.58, 1.10]					
	Lee 2019	-0.40047757		6.5%	0.67 [0.47, 0.95]					
	Liao 2020	-0.38566248		5.3%	0.68 [0.45, 1.03]					
	Lee 2020	-0.26136476		7.6%	0.77 [0.57, 1.04]					
	Simon 2020	-0.34249031	0.07968742	11.5%	0.71 [0.61, 0.83]					
	Subtotal (95% CI)			45.9%	0.75 [0.67, 0.83]		•			
	Heterogeneity: Tau ² = Test for overall effect:		•	54); I ² = 0%	ζο Ι					
	1.5.2 Non-DM									
	Ho 2018-HBV	-0.34249031	0 14887372	7.8%	0.71 [0.53, 0.95]					
	Ho 2018-HCV		0.12758427	8.9%	1.21 [0.94, 1.55]		+	-		
	Lee 2019	-0.32850407		9.3%	0.72 [0.57, 0.91]					
	Liao 2020	-0.71334989		9.3 <i>%</i> 6.9%	0.49 [0.35, 0.68]					
	Liao 2020 Lee 2020	-0.26136476		8.7%	0.49 [0.35, 0.88]					
	Simon 2020	-0.46203546	0.0605429	12.6%	0.63 [0.56, 0.71]		-			
	Subtotal (95% CI)	-0.40203340	0.0003423	54.1%	0.73 [0.59, 0.91]					
	Heterogeneity: Tau ² =	0.06° Chi ² = 26.46	df = 5 (P < 0				•			
	Test for overall effect:			.0001),1						
	Total (95% CI)			100.0%	0.74 [0.66, 0.84]		•			
		0 03. Chi2 - 30 72	df = 11 (P =	0 001)· l² :		+				_
	Heterogeneity: Tau ² = Test for overall effect:	Z = 4.83 (P < 0.00	001)			0.1 0.2	0.5 1	2	5	1
		Z = 4.83 (P < 0.00	001)		0%	0.1 0.2		_	5	1
	Test for overall effect: Test for subaroup diffe	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0	001) 4. df = 1 (P =	0.84). I ² =	0% Risk Ratio		Risk F	Ratio	-	1
_	Test for overall effect: Test for subaroup diffe Study or Subgroup	Z = 4.83 (P < 0.00	001) 4. df = 1 (P =	0.84). I ² =	0%		Risk F	_	-	1
_	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio]	001) 4. df = 1 (P = <u>SE</u>	0.84). ² = <u>Weight</u>	0% Risk Ratio IV, Random, 95% CI		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339	001) 4. df = 1 (P = <u>SE</u> 0.10838857	0.84). I ² = <u>Weight</u> 13.3%	0% Risk Ratio <u>IV, Random, 95% CI</u> 0.84 [0.68, 1.04]		Risk F	Ratio	-	1
_	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262	0.84). I ² = <u>Weight</u> 13.3% 13.5%	0% Risk Ratio <u>IV. Random. 95% CI</u> 0.84 [0.68, 1.04] 0.99 [0.81, 1.21]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034 -0.07257069	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1%	0% Risk Ratio <u>IV. Random. 95% CI</u> 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24]		Risk F	Ratio	-	1
_	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034 -0.07257069 -0.28768207	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5%	0% Risk Ratio IV. Random. 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034 -0.07257069	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2%	0% Risk Ratio IV. Random. 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI)	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207	001) 4. df = 1 (P = 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5%	0% Risk Ratio IV. Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94,	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5%	0% Risk Ratio IV. Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² =	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 log[Risk Ratio] -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94,	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5%	0% Risk Ratio IV. Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect:	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5%	0% Risk Ratio IV. Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); I ² = 19	0% Risk Ratio IV, Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] %		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00 -0.597837	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); I ² = 19 2.9%	0% Risk Ratio IV, Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HBV Lee 2019 Lee 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HCV	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00 -0.597837 0.44468582	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); I ² = 19 2.9% 3.8%	0% Risk Ratio IV, Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HEV Lee 2019 Lee 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553 0.3062697	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); I ² = 19 2.9% 3.8% 11.7%	0% Risk Ratio IV, Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Subtotal (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553	0.84). I ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); I ² = 19 2.9% 3.8% 11.7% 5.1%	0% Risk Ratio IV, Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74] 0.75 [0.41, 1.37]		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207 -0.5798185 0.04; Chi ² = 7.68,	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553 0.3062697 0.09624853 df = 4 (P = 0.1	0.84). ² = <u>Weight</u> 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); ² = 19 2.9% 3.8% 11.7% 5.1% 14.0% 37.5%	0% Risk Ratio IV. Random. 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74] 0.75 [0.41, 1.37] 0.56 [0.46, 0.68] 0.64 [0.50, 0.83]		Risk F	Ratio	-	
	Test for overall effect: Test for subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207 -0.5798185 0.04; Chi ² = 7.68,	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553 0.3062697 0.09624853 df = 4 (P = 0.1	0.84). ² = Weight 13.3% 13.5% 11.1% 10.5% 14.2% 62.5% 29); ² = 19 2.9% 3.8% 11.7% 5.1% 14.0% 37.5% 10); ² = 48	0% Risk Ratio IV. Random, 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74] 0.75 [0.41, 1.37] 0.56 [0.46, 0.68] 0.64 [0.50, 0.83] %		Risk F	Ratio	-	1
	Test for overall effect: Test for subaroup diffe Study or Subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: Total (95% CI)	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207 -0.5798185 0.04; Chi ² = 7.68, Z = 3.37 (P = 0.00)	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553 0.3062697 0.09624853 df = 4 (P = 0.1 07)	0.84). ² = Weight 13.3% 13.5% 13.5% 11.1% 10.5% 14.2% 62.5% 29); ² = 19 2.9% 3.8% 11.7% 5.1% 14.0% 37.5% 10); ² = 48 100.0%	0% Risk Ratio IV. Random. 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74] 0.75 [0.41, 1.37] 0.56 [0.46, 0.68] 0.64 [0.50, 0.83] %	IV,	Risk F	Ratio	-	
	Test for overall effect: Test for subgroup 1.6.1 Cirrhosis Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect: 1.6.2 Non-cirrhosis Ho 2018-HBV Ho 2018-HBV Ho 2018-HCV Lee 2019 Lee 2020 Simon 2020 Subtotal (95% CI) Heterogeneity: Tau ² = Test for overall effect:	Z = 4.83 (P < 0.00 erences: Chi ² = 0.0 -0.17435339 -0.01005034 -0.07257069 -0.28768207 -0.28768207 0.00; Chi ² = 4.94, Z = 2.88 (P = 0.00) -0.597837 0.44468582 -0.56211892 -0.28768207 -0.5798185 0.04; Chi ² = 7.68, Z = 3.37 (P = 0.00)	001) 4. df = 1 (P = <u>SE</u> 0.10838857 0.10448262 0.14791288 0.16004995 0.09257793 df = 4 (P = 0.2 4) 0.43789185 0.37563063 0.13604553 0.3062697 0.09624853 df = 4 (P = 0.1 07) df = 9 (P = 0	0.84). ² = Weight 13.3% 13.5% 13.5% 11.1% 10.5% 14.2% 62.5% 29); ² = 19 2.9% 3.8% 11.7% 5.1% 14.0% 37.5% 10); ² = 48 100.0%	0% Risk Ratio IV. Random. 95% CI 0.84 [0.68, 1.04] 0.99 [0.81, 1.21] 0.93 [0.70, 1.24] 0.75 [0.55, 1.03] 0.75 [0.63, 0.90] 0.85 [0.76, 0.95] % 0.55 [0.23, 1.30] 1.56 [0.75, 3.26] 0.57 [0.44, 0.74] 0.75 [0.41, 1.37] 0.56 [0.46, 0.68] 0.64 [0.50, 0.83] %	IV,	Risk F	Ratio	<u></u>	1

FIGURE 4 | Subgroup analyses for the meta-analysis of the association between aspirin use and HCC incidence in patients with HBV or HCV infection. (A) Subgroup analyses according to diabetic status. (B) Subgroup analyses in patients with and without cirrhosis.

Study or Subgroup 1.7.1 Shortest category Hwang 2018 Liao 2020 Simon 2020 Subtotal (95% CI)	log[Risk Ratio] y -0.38566248 -0.46203546		weight	IV, Random, 95% CI	I	V, Rano	<u>dom, y</u>	<u>15% C</u>	
Hwang 2018 Liao 2020 Simon 2020 Subtotal (95% CI)	-0.38566248	0.14771272							
Liao 2020 Simon 2020 Subtotal (95% CI)		0.14771272	47.00/	0 60 10 51 0 011			-		
Simon 2020 Subtotal (95% CI)	-0.46203546		17.8%	0.68 [0.51, 0.91]					
Subtotal (95% CI)			18.6%	0.63 [0.48, 0.83]					
	-0.13926207	0.09134257	23.4%	0.87 [0.73, 1.04]					
	00 01 12 4 55		59.8%	0.74 [0.60, 0.91]					
Heterogeneity: Tau ² = 0 Test for overall effect: Z		•	10); 1² = 56	%					
1.7.3 Longest category	/								
Hwang 2018	-0.67334455	0.22268885	12.0%	0.51 [0.33, 0.79]		•			
Liao 2020	-0.7985077	0.28350799	8.8%	0.45 [0.26, 0.78]					
Simon 2020	-0.56211892	0.13031266	19.5%	0.57 [0.44, 0.74]	-	-			
Subtotal (95% CI)			40.2%	0.54 [0.44, 0.66]	•	\bullet			
Heterogeneity: $Tau^2 = 0$			72); I² = 0%	0					
Test for overall effect: Z	= 5.92 (P < 0.00	001)							
Total (95% CI)			100.0%	0.64 [0.53, 0.78]		•		<u> </u>	
Heterogeneity: $Tau^2 = 0$		•	$.02); 1^2 = 6$	2%	(0.5 0.7	1 1	.5 2	
Test for overall effect: Z			0.04) 12	70.00/					
Test for subaroup differe	ences: $Chi^2 = 4.3$	3. df = 1 (P =	0.04). $I^2 =$						
				Risk Ratio			k Rati		
Study or Subgroup		SE	Weight	IV, Random, 95% CI	I	V, Rano	<u>dom, 9</u>	<u>15% C</u>	
1.10.1 Followed < 5 yea									
Lee 2017	-1.34707365		1.5%	0.26 [0.09, 0.75]					
Ho 2018-HBV	-0.19845094		13.6%	0.82 [0.67, 1.01]					
Ho 2018-HCV		0.09935326	14.1%	1.02 [0.84, 1.24]			T		
Liao 2020	-0.5798185	0.13149643	11.5%	0.56 [0.43, 0.72]					
Subtotal (95% CI)			40.7%	0.72 [0.51, 1.01]			1		
Heterogeneity: Tau ² = 0			.0005); l² =	= 83%					
Test for overall effect: Z	= 1.91 (P = 0.06)							
1.10.2 Followed \ge 5 ye	ears								
Hwang 2018	-0.43078292	0.10820338	13.3%	0.65 [0.53, 0.80]		-	-		
Lee 2019	-0.34249031	0.10048579	14.0%	0.71 [0.58, 0.86]		-	•		
Lee 2020	-0.24846136	0.10076373	14.0%	0.78 [0.64, 0.95]		-	•		
Simon 2020	-0.37106368	0.05193851	18.0%	0.69 [0.62, 0.76]					
Subtotal (95% CI)			59.3%	0.70 [0.65, 0.76]					
Heterogeneity: Tau ² = 0	.00; Chi² = 1.72,	df = 3 (P = 0.6	63); I² = 0%	0					
Test for overall effect: Z	= 9.10 (P < 0.00	001)							
Total (95% CI)			100.0%	0.73 [0.64, 0.83]			♦		
Heterogeneity: Tau ² = 0			.002); I² =	70%	0.05	0.2	1	5	20
Test for overall effect: Z	•				0.00	0.2	1	5	20
Test for subaroup differe	ences: Chi ² = 0.0	1. df = 1 (P =	0.91). I² =	0%					
5 Subgroup analyses for the	meta-analysis of the	association bot	ween senirin	use and HCC incidence in r	ationte with		HCV in	fection	(۸)

the association between aspirin use and reduced risk of HCC in these patients was weakened in studies with adjustment of statin use compared with that in studies without adjustment of statin use. In addition, aspirin use was also associated with an increased risk of GIB in these patients. Taken together, these findings indicated that aspirin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection, whereas the risk of GIB may be increased. Randomized controlled trials (RCTs) should be performed to validate these findings and weigh the benefit and risk of aspirin use in patients with HBV or HCV infection.

As far as we know, our study is the first meta-analysis that focused on the association between aspirin use and HCC risk in patients with HBV or HCV infection. We only included cohort

А					Risk Ratio	Risk Ratio
	Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	
	1.11.1 Antiviral treatr	•••••••				
	Lee 2019	-0.34249031	0.10048579	14.0%	0.71 [0.58, 0.86]	-
	Simon 2020	-0.37106368		18.0%	0.69 [0.62, 0.76]	•
	Subtotal (95% CI)			32.0%	0.69 [0.63, 0.76]	♦
	Heterogeneity: Tau ² =	0.00; Chi ² = 0.06,	df = 1 (P = 0.8	80); I ² = 0%	/ 0	
	Test for overall effect:	Z = 7.91 (P < 0.00	001)			
	1.11.2 Antiviral treatr	nent not adjusted				
	Lee 2017	-1.34707365	0.53745932	1.5%	0.26 [0.09, 0.75]	
	Ho 2018-HBV	-0.19845094	0.10470099	13.6%	0.82 [0.67, 1.01]	-
	Ho 2018-HCV	0.01980263	0.09935326	14.1%	1.02 [0.84, 1.24]	+
	Hwang 2018	-0.43078292	0.10820338	13.3%	0.65 [0.53, 0.80]	-
	Liao 2020	-0.5798185	0.13149643		0.56 [0.43, 0.72]	-
	Lee 2020	-0.24846136	0.10076373	14.0%	0.78 [0.64, 0.95]	T
	Subtotal (95% CI)			68.0%	0.73 [0.59, 0.90]	•
	Heterogeneity: Tau ² =		•	.0009); l² =	= 76%	
	Test for overall effect:	Z = 3.00 (P = 0.00)	3)			
	Total (95% CI)			100.0%	0.73 [0.64, 0.83]	♦
	Heterogeneity: Tau ² =	0.02; Chi ² = 23.16	, df = 7 (P = 0	.002); l² =	70%	0.05 0.2 1 5 20
	Test for overall effect:	Z = 4.67 (P < 0.00	001)			0.05 0.2 1 5 20
	Test for subaroup diffe	erences: Chi ² = 0.1	9. df = 1 (P =)	0.66). I² =	0%	
в						
Б					Risk Ratio	Risk Ratio
-	Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
	1.12.1 Statin use adju			10.001		_
	Ho 2018-HBV	-0.19845094		13.6%	0.82 [0.67, 1.01]	1
	Ho 2018-HCV Lee 2019		0.09935326	14.1%	1.02 [0.84, 1.24]	_
	Lee 2019	-0.34249031 -0.24846136		14.0% 14.0%	0.71 [0.58, 0.86] 0.78 [0.64, 0.95]	
	Simon 2020	-0.37106368		14.0%	0.69 [0.62, 0.76]	-
	Subtotal (95% CI)	-0.37 100300	0.00100001	73.7%	0.79 [0.68, 0.91]	•
	Heterogeneity: Tau ² =	0.02; Chi ² = 13.27	df = 4 (P = 0			
	Test for overall effect:			,		
	1.12.2 Statin use not	adjusted				
	Lee 2017	-1.34707365	0.53745932	1.5%	0.26 [0.09, 0.75]	
	Hwang 2018	-0.43078292	0.10820338	13.3%	0.65 [0.53, 0.80]	-
	Liao 2020		0.13149643	11.5%	0.56 [0.43, 0.72]	-
	Subtotal (95% CI)			26.3%	0.58 [0.46, 0.74]	◆
	Heterogeneity: Tau ² =	0.02; Chi ² = 3.24,	df = 2 (P = 0.2	20); I² = 38	%	
	Test for overall effect:	Z = 4.44 (P < 0.00	001)			
	Total (95% CI)			100.0%	0.73 [0.64, 0.83]	•
	Heterogeneity: Tau ² =	0.02; Chi ² = 23.16	, df = 7 (P = 0	.002); l² =	70%	
	Test for overall effect:		•			0.05 0.2 1 5 20
	Test for subaroup diffe	erences: Chi ² = 4.5	7. df = 1 (P =)	0.03). I² =	78.1%	
FIGURE	6 Subgroup analyses for the	he meta-analvsis of the	association bet	ween aspirin	use and HCC incidence in	patients with HBV or HCV infection. (A) Subgroup
	according to the adjustmen					

studies with multivariate analyses, which therefore provided an independent association between aspirin use and a reduced risk of HCC in these patients. Because no RCTs have been performed regarding the preventative efficacy of aspirin for HCC, even in high-risk patients such as those with HBV or HCV infection, our study highlights the necessity to perform such studies. Sensitivity analyses and multiple subgroup analyses were performed to evaluate the robustness of the results. We found that the

Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	Risk Ratio IV, Random, 95% Cl
_ee 2017	0.10436002	0.42503399	1.9%	1.11 [0.48, 2.55]	
_ee 2019	0.12221763	0.09882179	34.8%	1.13 [0.93, 1.37]	+=
_ee 2020	0.11332868	0.11556277	25.4%	1.12 [0.89, 1.40]	-+
Simon 2020	0.16551444	0.09468776	37.9%	1.18 [0.98, 1.42]	
Fotal (95% CI)			100.0%	1.15 [1.02, 1.28]	•
-leterogeneity: Tau ² =	0.00; Chi² = 0.16, o	df = 3 (P = 0.9	98); I² = 0%		
Test for overall effect:	Z = 2.33 (P = 0.02))			0.5 0.7 1 1.5 2

FIGURE 7 | Forest plots for the meta-analysis of the association between aspirin use and GIB incidence in patients with HBV or HCV infection.




FIGURE 8 | Publication bias analysis. (A) Funnel plots with trim-and-fill analysis for the association between aspirin use and HCC incidence in patients with HBV or HCV infection. (B) Forest plots incorporating the hypothesized study for the meta-analysis of the association between aspirin use and HCC incidence in patients with HBV or HCV infection. Black square in (A) represents the hypothesized unpublished study with negative results, and incorporating this study achieved symmetrical funnel plots. Study H1 in (B) represents the datasets of the hypothesized unpublished study and including this study in the meta-analysis did not change the results significantly.

results of the meta-analysis were not significantly affected by either of the individual included studies. Besides, the association between aspirin use and reduced HCC risk was significant regardless of the age, sex, viral status, diabetic status, the cirrhotic status of the patients, and follow-up durations. Moreover, the association between aspirin use and reduced HCC risk was not significantly affected by the adjustment of antiviral treatment, whereas significantly weakened in studies with adjustment of statin use compared with that in studies without adjustment of statin use. A previous meta-analysis showed that statin use was associated with a reduced incidence of HCC in patients with HBV/HCV infection. Moreover, aspirin is commonly prescribed in conjunction with a hypocholesterolemic agent such as a statin, which may confound the association between aspirin and reduced HCC risk in these patients. Our subgroup analyses showed that the association between aspirin and reduced HCC risk remains significant in subgroups, including studies with adjustment of statin use, which further supported a potential independent association between aspirin and reduced HCC risk in these patients.

The mechanisms underlying the association between aspirin use and reduced HCC risk may be multifactorial. An early study showed that aspirin inhibited HCV RNA and protein expression through cyclooxygenase-2 signal pathways (32), contributing to their anticancer efficacy in HCV-related HCC. Besides, aspirin could inhibit HCV entry via downregulation of claudin-1, thereby further inhibiting HCV replication, which could also be responsible for a reduced HCC risk in patients with HCV infection (33). Another study in the mice model of chronic HBV infection showed that antiplatelet therapy with aspirin or clopidogrel prevented HCC and improved survival in mice model of chronic HBV infection via amelioration of immune-mediated chronic liver injury by overactivated platelets (34, 35). Moreover, cirrhosis has been associated with an increased risk of HCC in patients with HBV or HCV infection (36). Aspirin use has been related to reduced liver fibrosis progression (37), which may be another important mechanism underlying its association with reduced HCC risk. The exact mechanisms underlying the association between aspirin use and reduced HCC risk in patients with HBV or HCV infection deserve further studies.

We found that aspirin use may be associated with an increased risk of GIB in patients with HBV or HCV infection. These results should be validated because only four datasets were available. Currently, we could not determine the potential patient characteristics and concurrent medication on the association between aspirin use and GIB risk, as these data were rarely reported in the included studies. For example, decompensated cirrhotic patients are vulnerable to variceal bleeding, and the use of aspirin may expose these patients to a higher risk of GIB (38). Therefore, it could be hypothesized that aspirin may increase the risk of GIB primarily in HBV- or HCV-infected patients with cirrhosis. Accordingly, prophylactic medications for GIB, such as proton pump inhibitors (PPIs), are often prescribed in these patients, particularly when aspirin is indicated. However, the use of PPIs in cirrhotic patients has been related to increased risks of adverse events such as hepatic encephalopathy, spontaneous bacterial peritonitis, and possibly HCC and mortality (39, 40). Therefore, the influence of aspirin use in cirrhotic patients with HBV or HCV infection may be much more complicated in realworld clinical practice, which warrants delicately designed RCTs to evaluate the potential benefits on HCC and risks of GIB.

Our study has limitations that should be noticed when interpreting the results. Firstly, significant heterogeneity was detected among the included studies. Although some subgroup analyses were performed to evaluate the patient characteristics on the outcome, we could not exclude other factors that may contribute to the heterogeneity, such as concurrent medications, alcohol intake, dietary factors, among others (41). Secondly, limited studies were included for the subgroup analyses, the results of which should be interpreted cautiously. Thirdly, antiviral therapy outcome was not considered when subgroup analysis according to the adjustment of antiviral therapy was performed. This is because none of the included studies provided any data according to the outcome of antiviral therapy. Fourthly, publication bias may exist, although a trim-and-fill study was performed and showed similar results. Furthermore, although we included studies with adjusted data, three are chances that residual factors may confound the association. Besides, a causative association between aspirin use and reduced HCC risk in HBV- or HCV-infected patients could not be derived based on our study, as this is a meta-analysis of observational studies. In addition, a potential time-dependent and dose-dependent association between aspirin use and reduced HCC in HBV- or HCV-infected patients was not observed due to the inconsistent cutoffs for the duration and dose of aspirin exposure in the included studies. Moreover, the loss of follow-up in the cohort study is an important issue that affects the outcome, which may also affect the results of our meta-analysis. Finally, the net benefits or harms of aspirin use in HBV- or HCV-infected patients could not be determined based on our study. Large-scale RCTs should be performed to weigh the benefit and risk of aspirin use in patients with HBV or HCV infection considering the cirrhotic status and concurrent medications, such as PPIs.

In conclusion, the results of the meta-analysis showed that aspirin use was independently associated with a reduced risk of HCC in patients with HBV or HCV infection, whereas the risk of GIB may be increased. Large-scale RCTs are needed to validate these findings and weigh the benefit and risk of aspirin use in patients with HBV or HCV infection.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/supplementary material.

AUTHOR CONTRIBUTIONS

XL conceived and designed the study and drafted the paper. XL and SW selected the studies and collected the data. XL and YY analyzed data. All authors interpreted the results, revised the draft paper and read and approved the final version of the manuscript.

REFERENCES

- Mcglynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology*. (2020). doi: 10.1002/hep.31288. [Epub ahead of print].
- Craig AJ, Von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. *Nat Rev Gastroenterol Hepatol.* (2020) 17:139–52. doi: 10.1038/s41575-019-0229-4
- Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. (2020) 72:250– 61. doi: 10.1016/j.jhep.2019.08.025
- Mak LY, Cruz-Ramon V, Chinchilla-Lopez P, Torres HA, Loconte NK, Rice JP, et al. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. (2018) 38:262– 79. doi: 10.1200/EDBK_200939
- Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. *Gastroenterology*. (2019) 157:54– 64. doi: 10.1053/j.gastro.2019.02.049
- Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. *Gastroenterology*. (2019) 156:477–91 e471. doi: 10.1053/j.gastro.2018.08.065
- Roderburg C, Tacke F, Trautwein C. Antiviral therapy in patients with viral hepatitis and hepatocellular carcinoma: indications and prognosis. *Visc Med.* (2016) 32:121–6. doi: 10.1159/000444990
- Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. *Hepat Oncol.* (2018) 5:HEP03. doi: 10.2217/hep-2017-0024
- Bangaru S, Marrero JA, Singal AG. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. *Aliment Pharmacol Ther.* (2019) 51:78–89. doi: 10.1111/apt.15573
- Michiels JJ. Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. *Pathol Biol.* (2003) 51:167–75. doi: 10.1016/S0369-8114(03)00038-5
- Palacios-Acedo AL, Mege D, Crescence L, Dignat-George F, Dubois C, Panicot-Dubois L. Platelets, thrombo-Inflammation, and cancer: collaborating with the enemy. *Front Immunol.* (2019) 10:1805. doi: 10.3389/fimmu.2019.01805
- Veronese N, Demurtas J, Thompson T, Solmi M, Pesolillo G, Celotto S, et al. Effect of low-dose aspirin on health outcomes: an umbrella review of systematic reviews and meta-analyses. *Br J Clin Pharmacol.* (2020) 86:1465– 75. doi: 10.1111/bcp.14310
- Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. *Med Res Rev.* (2019) 39:114–45. doi: 10.1002/med.21514
- Wang Y, Zhao J, Chen X, Zhang F, Li X. Aspirin use and endometrial cancer risk: a meta-analysis and systematic review. *Ann Transl Med.* (2020) 8:461. doi: 10.21037/atm.2020.03.125
- Niikura R, Hirata Y, Hayakawa Y, Kawahara T, Yamada A, Koike K. Effect of aspirin use on gastric cancer incidence and survival: a systematic review and meta-analysis. *JGH Open.* (2020) 4:117–25. doi: 10.1002/jgh3.12226
- Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. (2020) 31:558–68. doi: 10.1016/j.annonc.2020.02.012
- Sun J, Li Y, Liu L, Jiang Z, Liu G. Aspirin use and pancreatic cancer risk: a systematic review of observational studies. *Medicine*. (2019) 98:e18033. doi: 10.1097/MD.00000000018033
- Lee M, Chung GE, Lee JH, Oh S, Nam JY, Chang Y, et al. Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment. *Hepatology*. (2017) 66:1556–569. doi: 10.1002/hep.29318
- Ho CM, Lee CH, Lee MC, Zhang JF, Wang JY, Hu RH, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study. *BMC Cancer.* (2018) 18:401. doi: 10.1186/s12885-018-4292-y
- Hwang IC, Chang J, Kim K, Park SM. Aspirin use and risk of hepatocellular carcinoma in a national cohort study of korean adults. *Sci Rep.* (2018) 8:4968. doi: 10.1038/s41598-018-23343-0

- Lee TY, Hsu YC, Tseng HC, Yu SH, Lin JT, Wu MS, et al. Association of daily aspirin therapy with risk of hepatocellular carcinoma in patients with chronic hepatitis b. *JAMA Intern Med.* (2019) 179:633–40. doi: 10.1001/jamainternmed.2018.8342
- Lee TY, Hsu YC, Tseng HC, Lin JT, Wu MS, Wu CY. Association of daily aspirin therapy with hepatocellular carcinoma risk in patients with chronic hepatitis c Virus infection. *Clin Gastroenterol Hepatol.* (2020) 18:2784-92.e7. doi: 10.1016/j.cgh.2020.04.036
- 23. Liao YH, Hsu RJ, Wang TH, Wu CT, Huang SY, Hsu CY, et al. Aspirin decreases hepatocellular carcinoma risk in hepatitis C virus carriers: a nationwide cohort study. *BMC Gastroenterol.* (2020) 20:6. doi: 10.1186/s12876-020-1158-y
- Simon TG, Duberg AS, Aleman S, Chung RT, Chan AT, Ludvigsson JF. Association of aspirin with hepatocellular carcinoma and liver-related mortality. N Engl J Med. (2020) 382:1018–28. doi: 10.1056/NEJMoa1912035
- 25. Wang S, Yu Y, Ryan PM, Dang M, Clark C, Kontogiannis V, et al. Association of aspirin therapy with risk of hepatocellular carcinoma: a systematic review and dose-response analysis of cohort studies with 2.5 million participants. *Pharmacol Res.* (2020) 151:104585. doi: 10.1016/j.phrs.2019.104585
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008
- Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. (2011). www.cochranehandbook.org.
- Wells GA, Shea B, O'connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. (2010). Available online at: http://www.ohri.ca/ programs/clinical_epidemiology/oxford.asp.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. (2002) 21:1539–58. doi: 10.1002/sim.1186
- Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. *Int J Epidemiol.* (2008) 37:1148–57. doi: 10.1093/ije/dyn065
- Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ*. (1997) 315:629– 34. doi: 10.1136/bmj.315.7109.629
- Trujillo-Murillo K, Rincon-Sanchez AR, Martinez-Rodriguez H, Bosques-Padilla F, Ramos-Jimenez J, Barrera-Saldana HA, et al. Acetylsalicylic acid inhibits hepatitis c virus rNA and protein expression through cyclooxygenase 2 signaling pathways. *Hepatology*. (2008) 47:1462–72. doi: 10.1002/hep.22215
- Yin P, Zhang L. Aspirin inhibits hepatitis c virus entry by downregulating claudin-1. J Viral Hepat. (2016) 23:62–4. doi: 10.1111/jvh.12446
- 34. Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. *Proc Natl Acad Sci USA*. (2012) 109:E2165–72. doi: 10.1073/pnas.1209182109
- Sitia G. Platelets promote liver immunopathology contributing to hepatitis b virus-mediated hepatocarcinogenesis. *Semin Oncol.* (2014) 41:402– 5. doi: 10.1053/j.seminoncol.2014.04.013
- 36. Kanda T, Goto T, Hirotsu Y, Moriyama M, Omata M. Molecular mechanisms driving progression of liver cirrhosis towards hepatocellular carcinoma in chronic hepatitis b and C infections: a Review. *Int J Mol Sci.* (2019) 20:1358. doi: 10.3390/ijms20061358
- Jiang ZG, Feldbrugge L, Tapper EB, Popov Y, Ghaziani T, Afdhal N, et al. Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. *Aliment Pharmacol Ther.* (2016) 43:734– 43. doi: 10.1111/apt.13515
- O'leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA clinical practice update: coagulation in cirrhosis. *Gastroenterology*. (2019) 157:34–43 e31. doi: 10.1053/j.gastro.2019.03.070
- Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and metaanalysis. *Hepatol Int.* (2020) 14:385–98. doi: 10.1007/s12072-019-10010-3
- Wu X, Zhang D, Yu Y, Lou L, Li X. (2020) Proton pump inhibitor use and mortality in patients with cirrhosis: a meta-analysis of cohort studies. *Biosci Rep.* doi: 10.1042/BSR20193890

 Yang Y, Zhang D, Feng N, Chen G, Liu J, Zhu Y. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. *Gastroenterology*. (2014) 147:1031–42. doi: 10.1053/j.gastro.2014.08.005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Wu and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.